Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IQANNA is a brand of medical cannabis products, including dried flower and extracts, developed and supplied by Clever Leaves. These products are produced in Clever Leaves' GACP-certified and GMP-certified facilities in Portugal and Colombia and are distributed in international markets, notably Germany, through partnerships with companies like Ethypharm. The IQANNA brand encompasses various chemovars of *Cannabis sativa*, containing active cannabinoids such as delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). These cannabinoids interact with the human endocannabinoid system, primarily targeting CB1 and CB2 receptors to provide therapeutic effects. In Germany, these products are prescribed for a variety of conditions, including chronic pain, spasticity associated with multiple sclerosis, and chemotherapy-induced nausea, particularly when conventional treatments have proven insufficient.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on IQANNA.